JP2019505486A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019505486A5 JP2019505486A5 JP2018530079A JP2018530079A JP2019505486A5 JP 2019505486 A5 JP2019505486 A5 JP 2019505486A5 JP 2018530079 A JP2018530079 A JP 2018530079A JP 2018530079 A JP2018530079 A JP 2018530079A JP 2019505486 A5 JP2019505486 A5 JP 2019505486A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- osteoarthritis
- subject
- composition according
- cartilage
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562264682P | 2015-12-08 | 2015-12-08 | |
| US62/264,682 | 2015-12-08 | ||
| PCT/US2016/065520 WO2017100400A2 (en) | 2015-12-08 | 2016-12-08 | Use of c-type natriuretic peptide variants to treat osteoarthritis |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019505486A JP2019505486A (ja) | 2019-02-28 |
| JP2019505486A5 true JP2019505486A5 (cg-RX-API-DMAC7.html) | 2020-01-23 |
| JP7104625B2 JP7104625B2 (ja) | 2022-07-21 |
Family
ID=59013378
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018530079A Active JP7104625B2 (ja) | 2015-12-08 | 2016-12-08 | 骨関節炎を処置するためのｃ型ナトリウム利尿ペプチド変異体の使用 |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US11202819B2 (cg-RX-API-DMAC7.html) |
| EP (2) | EP4019038A3 (cg-RX-API-DMAC7.html) |
| JP (1) | JP7104625B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR20180088459A (cg-RX-API-DMAC7.html) |
| CN (1) | CN108697766A (cg-RX-API-DMAC7.html) |
| AU (2) | AU2016365751B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3007315A1 (cg-RX-API-DMAC7.html) |
| DK (1) | DK3386531T3 (cg-RX-API-DMAC7.html) |
| ES (1) | ES2901769T3 (cg-RX-API-DMAC7.html) |
| HR (1) | HRP20211908T1 (cg-RX-API-DMAC7.html) |
| HU (1) | HUE057083T2 (cg-RX-API-DMAC7.html) |
| IL (1) | IL259690B2 (cg-RX-API-DMAC7.html) |
| MX (1) | MX2018006986A (cg-RX-API-DMAC7.html) |
| PL (1) | PL3386531T3 (cg-RX-API-DMAC7.html) |
| PT (1) | PT3386531T (cg-RX-API-DMAC7.html) |
| RU (1) | RU2759679C2 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2017100400A2 (cg-RX-API-DMAC7.html) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11389511B2 (en) | 2016-01-08 | 2022-07-19 | Ascendis Pharma Growth Disorders A/S | Controlled-release CNP agonists with reduced side-effects |
| IL318754A (en) | 2016-01-08 | 2025-04-01 | Ascendis Pharma Growth Disorders As | Controlled-release CNP agonists with low initial NPR-B activity |
| EP3400021A1 (en) | 2016-01-08 | 2018-11-14 | Ascendis Pharma Growth Disorders A/S | Controlled-release cnp agonists with low npr-c binding |
| JP6968802B2 (ja) | 2016-01-08 | 2021-11-17 | アセンディス ファーマ グロース ディスオーダーズ エー／エス | 環部分にキャリア結合を有するｃｎｐプロドラッグ |
| MY195190A (en) | 2016-01-08 | 2023-01-11 | Ascendis Pharma Growth Disorders As | Controlled-Release Cnp Agonists With Increased Nep Stability |
| US10835578B2 (en) | 2016-01-08 | 2020-11-17 | Ascendis Pharma Growth Disorders A/S | CNP prodrugs with large carrier moieties |
| LT3518930T (lt) | 2016-09-29 | 2023-05-10 | Ascendis Pharma Growth Disorders A/S | Kompleksinė terapija su kontroliuojamo išskyrimo cnp agonistais |
| US20210228497A1 (en) * | 2018-04-27 | 2021-07-29 | Remy Biosciences, Inc. | New Medical Devices, Delivery Vehicles and Manufacturing Thereof |
| KR102893903B1 (ko) * | 2019-02-11 | 2025-12-01 | 아센디스 파마 그로우쓰 디스오더스 에이/에스 | Cnp 접합체의 건조 약학 제제 |
| CN116635027A (zh) * | 2020-11-25 | 2023-08-22 | 普罗林科斯有限责任公司 | C-利钠肽的延长释放水凝胶偶联物 |
| EP4337957A1 (en) * | 2021-05-11 | 2024-03-20 | Texas Tech University System | Targeted selenium conjugates as countermeasures for pathogenic viruses and cells |
| AU2022407450A1 (en) * | 2021-12-07 | 2024-07-11 | Biomarin Pharmaceutical Inc. | CNP Therapy |
| JP2025521254A (ja) | 2022-11-02 | 2025-07-08 | ノヴォ ノルディスク アー／エス | Ｃｎｐ化合物 |
| WO2024104922A1 (en) | 2022-11-14 | 2024-05-23 | Ascendis Pharma Growth Disorders A/S | Method of improving skeletal muscle function |
| WO2024194300A1 (en) | 2023-03-20 | 2024-09-26 | Ascendis Pharma Growth Disorders A/S | Method of treatment of a thoracolumbar deformity in a human subject with achondroplasia |
| KR20250098109A (ko) * | 2023-12-21 | 2025-07-01 | 주식회사 펩트론 | 나트륨이뇨 펩타이드 유사체 및 이의 용도 |
| CN117801123B (zh) * | 2024-02-29 | 2024-05-03 | 天津凯莱英生物科技有限公司 | 沃索利肽可溶性中间体、中间体制备方法及沃索利肽的制备方法 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5252714A (en) | 1990-11-28 | 1993-10-12 | The University Of Alabama In Huntsville | Preparation and use of polyethylene glycol propionaldehyde |
| JP2809533B2 (ja) | 1991-01-31 | 1998-10-08 | 壽之 松尾 | Ｃｎｐ類似体ペプチド |
| US5824784A (en) | 1994-10-12 | 1998-10-20 | Amgen Inc. | N-terminally chemically modified protein compositions and methods |
| IL142118A0 (en) | 2001-03-20 | 2002-03-10 | Prochon Biotech Ltd | Method and composition for treatment of skeletal dysplasias |
| CA2561530C (en) | 2004-03-31 | 2014-04-22 | Kazuwa Nakao | Therapeutic or prophylactic agent for arthritis |
| EP3446711A1 (en) * | 2004-03-31 | 2019-02-27 | Kazuwa Nakao | Composition for increasing body height |
| CA2705603A1 (en) | 2007-11-21 | 2009-05-28 | Biomarin Pharmaceutical Inc. | Variants of c-type natriuretic peptide |
| EP4029512A1 (en) * | 2009-05-20 | 2022-07-20 | BioMarin Pharmaceutical Inc. | Variants of c-type natriuretic peptide |
| WO2012088608A1 (en) * | 2010-12-27 | 2012-07-05 | Enobia Canada Limited Partnership | Compositions comprising natriuretic peptides and methods of use thereof |
-
2016
- 2016-12-08 KR KR1020187019166A patent/KR20180088459A/ko active Pending
- 2016-12-08 HR HRP20211908TT patent/HRP20211908T1/hr unknown
- 2016-12-08 US US15/779,049 patent/US11202819B2/en active Active
- 2016-12-08 JP JP2018530079A patent/JP7104625B2/ja active Active
- 2016-12-08 PT PT168528669T patent/PT3386531T/pt unknown
- 2016-12-08 CA CA3007315A patent/CA3007315A1/en active Pending
- 2016-12-08 RU RU2018124600A patent/RU2759679C2/ru active
- 2016-12-08 DK DK16852866.9T patent/DK3386531T3/da active
- 2016-12-08 EP EP21202207.3A patent/EP4019038A3/en active Pending
- 2016-12-08 ES ES16852866T patent/ES2901769T3/es active Active
- 2016-12-08 CN CN201680081329.2A patent/CN108697766A/zh active Pending
- 2016-12-08 WO PCT/US2016/065520 patent/WO2017100400A2/en not_active Ceased
- 2016-12-08 AU AU2016365751A patent/AU2016365751B2/en active Active
- 2016-12-08 EP EP16852866.9A patent/EP3386531B1/en active Active
- 2016-12-08 HU HUE16852866A patent/HUE057083T2/hu unknown
- 2016-12-08 MX MX2018006986A patent/MX2018006986A/es unknown
- 2016-12-08 PL PL16852866T patent/PL3386531T3/pl unknown
-
2018
- 2018-05-29 IL IL259690A patent/IL259690B2/en unknown
-
2021
- 2021-12-03 US US17/541,992 patent/US12214015B2/en active Active
-
2024
- 2024-03-21 AU AU2024201852A patent/AU2024201852A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019505486A5 (cg-RX-API-DMAC7.html) | ||
| RU2018124600A (ru) | Применение вариантов натрийуретического пептида типа с для лечения остеоартрита | |
| JP2016512552A (ja) | リツキシマブ導入療法とその後の酢酸グラチラマー療法 | |
| Voulgari et al. | Infliximab therapy in established rheumatoid arthritis: an observational study | |
| JP6208763B2 (ja) | 変形性関節症を治療するためのｐｅｄｆ−由来のポリペプチドの使用 | |
| RS57853B1 (sr) | Dozni režim fgf-18 jedinjenja | |
| Nakamagoe et al. | Polymyalgia rheumatica in a melanoma patient due to nivolumab treatment | |
| CN107661501A (zh) | 一种治疗强直性脊柱炎的药物组合物、药物靶点及其应用 | |
| Lejko-Zupanc et al. | A case of recurrent Candida parapsilosis prosthetic valve endocarditis: cure by medical treatment alone | |
| Sofat et al. | Recent clinical evidence for the treatment of osteoarthritis: what we have learned | |
| CN119546340A (zh) | 使用白细胞介素-17（il-17）拮抗剂选择性治疗肌腱病的方法 | |
| EP3865179B1 (en) | Hmgb1 derived peptide for treating or preventing a cartilage disorder | |
| TWI491407B (zh) | 色素上皮衍生因子衍生之多胜肽於治療骨性關節炎之用途 | |
| JP2021523894A5 (cg-RX-API-DMAC7.html) | ||
| Bandinelli et al. | Case report Stiff skin syndrome and myeloma successfully treated with autologous haematopoietic stem cell transplantation (HSCT) | |
| Fernandez et al. | Review of the novelties presented at the 2018 ECTRIMS Congress: 11th Post-ECTRIMS Meeting (II) | |
| KR20180035911A (ko) | Fgf-18 화합물을 포함하는 조합 조성물 | |
| Mohanan et al. | IGURATIMOD: A NOVEL SMALL MOLECULE DISEASE-MODIFYING ANTIRHEUMATIC DRUG FOR SEROPOSITIVE RHEUMATOID ARTHRITIS-A PROSPECTIVE OBSERVATIONAL STUDY | |
| Živković | Relapsing polychondritis: From etiopathogenesis to therapy | |
| WO2020257173A1 (en) | Method of treating the osteoarthritic joint | |
| Komlos | American College of Rheumatology/Association of Rheumatology Professionals (ACR/ARP) Annual Meeting (ACR Convergence 2020). Virtual-November 5-9, 2020 | |
| Jayashankar et al. | An uncommon variant of rare type of muscular dystrophy | |
| Tur | The European League Against Rheumatism (EULAR)-2020 Annual European E-Congress of Rheumatology. Virtual Conference-June 3-6, 2020 | |
| Kim et al. | S-699 Successful use of tocilizumab in a patient with lupus erosive arthritis | |
| HK40060107A (en) | Hmgb1 derived peptide for treating or preventing a cartilage disorder |